Mobeus-backed Focus named Deal of the Year
Image provided by Image Source, a former Mobeus investee company (www.imagesource.com)
Mobeus is delighted that the trade sale of Focus Pharmaceuticals to Amdipharm Mercury Group has been voted by the corporate finance community as the Deal of the Year (over £10 million) at the Insider Dealmaker Awards – East Midlands.
The judges commented, “This deal was widely voted as the stand out deal of the year.”
Focus, based in Burton upon Trent, is a leading supplier of niche generic pharmaceuticals in the UK. The company develops and licenses its own generics, in addition to selling third party generic and branded products.
Mobeus supported the management buyout of Focus in 2007. At the time, revenues were c. £12 million and the business was modestly profitable. Through the investment period, the business demonstrated strong growth – turnover grew threefold to just under £40 million and the business generated profits in excess of £6 million. Focus was one of seven investments realised by Mobeus in 2014.
Ashley Broomberg, Partner at Mobeus, commented:
“It was a privilege to be part of the Focus success story which is all down to the four members of this highly entrepreneurial and capable management team. The team has single-mindedly pursued its vision for value creation, delivering consistent and controlled growth in a competitive and regulated market. I am delighted to see this award as further recognition of the team’s success.”
– Ends –
Issued by Mobeus Equity Partners LLP, of 30 Haymarket, London SW1Y 4EX, registered in England & Wales number OC320577, authorised and regulated by the Financial Conduct Authority, number 456538. This material is for information only and does not constitute an offer to buy or sell an investment nor does it solicit any such invitation. The information contained in this email is believed to be accurate at the date of publication but no representation or warranty stated or implied is made or given by any person as to its accuracy or completeness and no responsibility or liability is accepted for any such information or opinion.